Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration
Authors
Mountzios, GRemon, J
Novello, S
Blais, N
Califano, Raffaele
Cufer, T
Dingemans, A
Liu, SV
Peled, N
Pennell, NA
Reck, M
Rolfo, C
Tan, D
Vansteenkiste, J
West, H
Besse, B
Affiliation
Department of Medical Oncology, Henry Dunant Hospital Center, Athens, GreeceIssue Date
2019
Metadata
Show full item recordCitation
Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, et al. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of >/= 1% by the U.S. Food and Drug Administration. Ann Oncol. 2019 Sep 3.Journal
Annals of OncologyDOI
10.1093/annonc/mdz295PubMed ID
31504132Additional Links
https://dx.doi.org/10.1093/annonc/mdz295Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz295
Scopus Count
Collections
Related articles
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
- Authors: Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R
- Issue date: 2016 May
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
- Authors: Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB, McKee AE, Keegan P, Pazdur R
- Issue date: 2017 Nov
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Authors: Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB
- Issue date: 2016 Apr 9
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
- Authors: Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R
- Issue date: 2019 Jan
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
- Authors: Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, KEYNOTE-042 Investigators.
- Issue date: 2019 May 4